The CEO of Volkswagen Group of America said it's another "important step forward in our efforts to make things right for our customers."
The Trump administration may take big steps backward on privacy, and put the country at greater risk from cyberattacks, say experts.
These are the stocks posting the largest moves after the bell, including Mondelez, Square and more.
A U.S. Senate committee urged regulators to launch a probe into whether EpiPen maker Mylan broke the law by preventing schools from purchasing competing allergy treatments.
Senate committee calls on FTC to review Mylan's business practices around its EpiPen product for possible anti-competitive behavior. CNBC's Meg Tirrell reports. The "Fast Money" traders weigh in.
At issue is how different kinds of companies are allowed to use customer data — and the distinction is worth billions.
"This is still another case of Donald Trump having a unique view about how our system works," ex-FCC Chairman Reed Hundt tells CNBC.
Christine Varney, former Assistant Attorney General, head of DOJ Antitrust division and former FTC Commissioner, discusses the antitrust and anti-competition worries surrounding the AT&T-Time Warner merger.
Christopher Sagers, Cleveland State University law professor, discusses the possible antitrust complications of the AT&T-Time Warner merger.
Two U.S. senators have also asked the Federal Trade Commission to look into Mylan's EpiPen sales to schools.
Sen. Amy Klobuchar (D-Minn.) discusses the call for the FTC to investigate Mylan and other "bad actors" over drug pricing rules.
Sen. Amy Klobuchar (D-Minn.) discusses legislation for EpiPen-like generic drugs to be more widely available, pricing controls and drug importation from Canada.
Sen. Amy Klobuchar (D-Minn.) discusses Mylan CEO Heather Bresch's comments on the EpiPen pricing controversy.
There needs to be more transparency in drug pricing, and Mylan still has a lot of questions to answer, Sen. Charles Grassley said Thursday.
Mylan raised the prices of 24 drug products more than 20 percent. One went up by 542 percent. Another by 444 percent.
Hedge fund Pershing Square Capital Management sold its entire stake of 9.8 million shares, The New York Times reports.
Herbalife is saying after two years of working with the FTC, the company understands the terms of the settlement, reports CNBC's Scott Wapner.
The "FMHR" traders and John Spallanzani, GFI Group Chief Macro Strategist, discuss Ackman's response to the FTC Herbalife settlement.
Robert Chapman, Chapman Capital, comments on Herbalife's $200M agreement with FTC, as well as his views on the future of its stock.
Tim Ramey, Pivotal Research Analyst, comments on the $200M Herbalife settlement with FTC.